STAT3 regulated ARF expression suppresses prostate cancer metastasis

Citations Over TimeTop 10% of 2015 papers

Abstract

Prostate cancer (PCa) is the most prevalent cancer in men. Hyperactive STAT3 is thought to be oncogenic in PCa. However, targeting of the IL-6/STAT3 axis in PCa patients has failed to provide therapeutic benefit. Here we show that genetic inactivation of Stat3 or IL-6 signalling in a Pten-deficient PCa mouse model accelerates cancer progression leading to metastasis. Mechanistically, we identify p19(ARF) as a direct Stat3 target. Loss of Stat3 signalling disrupts the ARF-Mdm2-p53 tumour suppressor axis bypassing senescence. Strikingly, we also identify STAT3 and CDKN2A mutations in primary human PCa. STAT3 and CDKN2A deletions co-occurred with high frequency in PCa metastases. In accordance, loss of STAT3 and p14(ARF) expression in patient tumours correlates with increased risk of disease recurrence and metastatic PCa. Thus, STAT3 and ARF may be prognostic markers to stratify high from low risk PCa patients. Our findings challenge the current discussion on therapeutic benefit or risk of IL-6/STAT3 inhibition.

Related Papers

• → Cancer-Associated PTEN Mutants Act in a Dominant-Negative Manner to Suppress PTEN Protein Function(2014)270 cited
• 위암에서 PTEN 발현 및 신생혈관 형성의 관련성(2005)
• → PTEN Gene Expression and Tamoxifen-Resistance in Steroid Hormone Receptor Positive Breast Cancer Patients, a cross-sectional study between 2006 and 2016(2020)
• The expression significance and associativity of ILK and PTEN in gastric cancer tissue(2008)
• → Η προβλεπτική αξία των μεταλλάξεων του γονιδίου PI3K και της απώλειας της έκφρασης του γονιδίου PTEN σε ασθενείς με πρώιμο καρκίνο μαστού που έλαβαν συμπληρωματική θεραπεία με τραστουζουμάμπη(2019)